全球用钾强化盐替代普通盐对心血管疾病和慢性肾病的影响
Global health outcomes from replacing dietary sodium chloride with potassium-enriched salt
研究估计全球范围内用钾强化盐替代普通盐每年可预防296万例死亡、1017万例新发病例和6940万伤残调整生命年,主要受益于高血压和慢性肾病。
研究评估了全球范围内用钾强化盐替代普通盐对心血管疾病和慢性肾病的影响,提供了量化健康益处和风险的依据。
Abstract
Potassium-enriched salt is a practical, low-cost population-level intervention for preventing non-communicable diseases. Here we modelled the health effects of replacing regular salt with potassium-enriched salt under five scenarios using comparative risk assessment: (1) replacement of all added salt; (2) replacement of discretionary salt used in home cooking and seasoning; (3) replacement of non-discretionary salt used in processed and restaurant foods; (4) replacement of discretionary salt among diagnosed hypertensives; and (5) replacement of discretionary salt among treated hypertensives. Worldwide replacement of all salt could prevent 2.96 (95% uncertainty interval 2.81–3.12) million deaths, 10.17 (9.59–10.70) million new cases and 69.43 (65.61–72.92) million disability-adjusted life years each year from cardiovascular disease and chronic kidney disease. These correspond to 14.6% deaths, 13.1% new cases and 16.5% disability-adjusted life years attributable to these conditions annually. Replacement of discretionary salt (1.85, 1.74–1.97 million) would prevent more deaths than replacement of non-discretionary salt (1.56, 1.46–1.67 million). Targeting only diagnosed or treated hypertensives would prevent 0.59 million (0.55–0.63) and 0.48 million (0.45–0.52) deaths, respectively. In people with advanced chronic kidney disease, replacing all salt might cause 0.10 (0.09–0.11) million deaths from hyperkalaemia but would prevent 0.75 (0.71–0.80) million deaths from blood pressure lowering. These findings support the switch from regular salt to potassium-enriched salt.
Main
Cardiovascular disease (CVD) remains the leading cause of death globally, and chronic kidney disease (CKD) is projected to become the fifth leading cause of years of life lost by 20401. High blood pressure (BP) is a leading modifiable risk factor for CVD and CKD accounting for more than 10 million cardiovascular deaths and almost 0.5 million CKD deaths in 20212. Reducing sodium intake and increasing potassium intake are two dietary interventions that reduce BP. Current average global sodium intake (4.3 g per day) exceeds the World Health Organization (WHO) recommendation of 2.0 g per day3, and the Global Burden of Disease Study (GBD) identifies excess sodium intake as the leading dietary risk for CVD4. In the meantime, average global potassium intake is 2.3 g per day5, which is substantially below the WHO’s recommended minimum intake of 3.5 g per day6. In 2013, the member states of the United Nations committed to reducing population sodium intake by 30% by 20253. Despite substantial focus by the WHO and member states, no country is projected to meet this goal3.
The key challenge with current efforts focused on cutting sodium intake is that they require acceptance of a less salty taste and this has proved largely insurmountable for consumers and the food industry worldwide3. By contrast, switching to potassium-enriched salt simultaneously lowers sodium intake and increases potassium intake and can be done with no detectable effect on taste for most people and excellent overall acceptability7. Beneficial effects of potassium-enriched salt on BP are long established, and recent large trials and overviews of the trials have shown parallel reductions in the risks of major cardiovascular events and premature death8,9. In the largest and longest trial done so far, 92% of participants in the intervention group were still using a product with a composition of 25% potassium chloride and 75% sodium chloride after 5 years8.
A potential adverse consequence of increasing potassium intake is the risk of hyperkalaemia in people with CKD. So far, the majority of trials have asked participants to self-exclude if they are at elevated risk of hyperkalaemia and there is no evidence of clinical harm in any study or overview9. One trial that included all participants from elderly care facilities, irrespective of kidney function, showed an increased risk of biochemical hyperkalaemia, but there was no increase in adverse clinical outcomes10.
Prior modelling has projected large net health gains with potassium-enriched salt for China11, India12 and Indonesia13. Using an adapted model (Fig. 1) from previous modelling studies11,12, the aim of this study was to estimate the benefits and potential harms of a switch from regular salt to potassium-enriched salt under a range of different possible intervention scenarios for 193 countries, namely (1) worldwide replacement of all salt including both discretionary salt (that is, used for seasoning or cooking in the home) and non-discretionary salt (that is, in processed and restaurant foods including salty sauces and condiments); (2) worldwide replacement of just discretionary salt; (3) worldwide replacement of just non-discretionary salt; (4) worldwide replacement of discretionary salt just for people diagnosed with hypertension (whether treated or not); and (5) worldwide replacement of discretionary salt just for people treated for hypertension.
The model first estimates the impact of different strategies for replacing regular salt (100% NaCl) with potassium-enriched salt (75% NaCl and 25% KCl) on dietary sodium and potassium intake. Changes in sodium and potassium intake are then translated into changes in SBP, which are used to estimate subsequent effects on the risks of CVD and CKD. The model also estimates changes in serum potassium concentrations among individuals with CKD stages G3–G5 and the potential number of cardiovascular deaths attributable to hyperkalaemia in this population. Net deaths averted are calculated as the number of deaths prevented through SBP reduction minus the number of deaths attributable to hyperkalaemia. Net effects on incident disease cases and DALYs include only the effects mediated through blood pressure reduction. Model inputs and detailed information are presented in Supplementary Table 1. PIF, potential impact fraction.
Results
Effects of replacing both discretionary and non-discretionary salt
Switching from regular salt to potassium-enriched salt worldwide was estimated to avert 2.96 (95% uncertainty interval (UI) 2.81–3.12) million deaths, 10.17 (9.59–10.70) million new cases, and 69.4 (65.6–72.9) million disability-adjusted life years (DALYs) from CVD or CKD each year (Table 1). These figures represent 14.6%, 13.1% and 16.5% of the annual global disease burden attributable to CVD and CKD. For every metric, the greatest disease burden averted was for ischaemic heart disease, hypertensive heart disease, stroke and CKD (Extended Data Fig. 1). The greatest absolute benefits were in China and India, which have large populations and high levels of salt consumption (Fig. 2 and Extended Data Figs. 2 and 3), but there were 133/193 (69%) countries, predominantly in Asia, North America and Latin America, where at least 10% of cardiovascular deaths would be prevented by switching to potassium-enriched salt (Fig. 3 and Supplementary Table 3). Overall, about 40% of the benefits are achieved in women, and this finding was broadly consistent across intervention strategies (Supplementary Table 3).
Maps illustrate the median annual number of net deaths averted following replacement of regular salt (100% NaCl) with potassium-enriched salt (75% NaCl and 25% KCl) under different implementation scenarios. Net deaths averted were calculated as deaths prevented through blood pressure reduction minus deaths attributable to hyperkalaemia among individuals with stage G3–G5 CKD. Median estimates were derived from 1,000 Monte Carlo simulations. Basemaps from Natural Earth (http://www.naturalearthdata.com).
Maps illustrate the estimated median proportion of national deaths from CVD and CKD averted following replacement of regular salt (100% NaCl) with potassium-enriched salt (75% NaCl and 25% KCl) under different implementation scenarios. The number of deaths under the status quo was estimated using data from the Global Burden of Disease Study 2021 and propagated through 1,000 Monte Carlo simulations. Net deaths averted were calculated as deaths prevented through blood pressure reduction minus deaths attributable to hyperkalaemia among individuals with stage G3–G5 CKD. The proportion of deaths averted was calculated relative to the total number of deaths under the status quo from the modelled diseases and estimated in each simulation; the median across simulations is presented. Basemaps from Natural Earth (http://www.naturalearthdata.com).
Effects of replacing discretionary salt alone
Switching just discretionary salt use to potassium-enriched salt was estimated to avert 1.85 (95% UI 1.74–1.97) million deaths, equating to 63% (1.85/2.96) (further explained in Supplementary Text 1) of the benefit achieved with switching both discretionary and non-discretionary salt, and 9.2% of annual deaths attributable to CVD and CKD (Table 1). There were correspondingly lower proportions of new cases and DALYs averted with this approach, but the pattern of prevention across the main causes of CVD and CKD was similar to that observed for switching discretionary and non-discretionary salt together (Extended Data Fig. 1). The geographic distributions of the absolute and proportional benefits were also similar (Figs. 2 and 3 and Extended Data Figs. 2–5). Switching discretionary salt use for China, India, Indonesia and Russia would achieve over 60% of the total global benefits (Extended Data Figs. 6–8), but only 58/193 (30.1%) countries would prevent 10% or more of CVD deaths each year with a strategy targeting discretionary salt alone (Fig. 3 and Supplementary Table 3).
Effects of replacing non-discretionary salt alone
Switching non-discretionary salt use alone would prevent 1.56 (95% UI 1.46–1.67) million deaths, which is 53% (1.56/2.96) (further explained in Supplementary Text 1) of the benefit achieved with switching both discretionary and non-discretionary salt. Prevention of new cases and DALYs would be similarly lower (Table 1) and the pattern of prevention across CVD and CKD subtypes would be broadly similar to other strategies (Extended Data Fig. 1). The projected health gain equates to 7.7% of annual deaths from CVD and CKD worldwide. The USA displaces Russia as one of the four countries projected to achieve the greatest benefit from this strategy which reflects the predominance of non-discretionary salt as the dietary source of sodium in the USA (Extended Data Figs. 6–8 and Supplementary Table 3). There were only 20/193 (10%) countries achieving a 10% or greater reduction in cardiovascular deaths with an intervention strategy focused on non-discretionary salt alone (Fig. 3 and Supplementary Table 3).
Effects of replacing discretionary salt among people with diagnosed hypertension, treated hypertension or CKD
Replacing discretionary salt with potassium-enriched salt for just the 658 million people with diagnosed hypertension would prevent 0.59 (0.55–0.63) million deaths, and among the 523 million people with treated hypertension would prevent 0.48 (0.45–0.52) million deaths (Table 1). Among the 239 million adults worldwide with CKD stage G3 to G5, there would be 0.75 (95% UI 0.71–0.80) million CVD deaths prevented by switching discretionary and non-discretionary salt to potassium-enriched salt. This benefit would, however, be associated with the potential for causing 0.10 (0.09–0.11) million deaths from hyperkalaemia (Table 2 and Supplementary Table 4).
Sensitivity analyses
In the deterministic sensitivity analyses, the magnitude of the estimated benefit varied across assumptions, but there were still large net benefits under each. Half replacement of all regular salt in all adults could avert 1.72 million deaths, and one-fifth replacement could avert 0.7 million deaths. We did seven further sensitivity analyses on the effects of full replacement of all regular salt in all adults: (1) attenuated dose–response between sodium reduction and systolic BP (SBP); (2) additive effects of sodium reduction and potassium increase on BP reduced from 100% to 80%; (3) effect of potassium supplementation on BP reduced by half; (4) no effect of potassium supplementation in non-hypertensive individuals; (5) for a salt substitute with a composition of 15% potassium chloride and 85% sodium chloride; (6) plateauing of the effect when sodium intake is reduced to 2.5 g per day; and (7) plateauing of the effect when sodium intake is reduced to 3.0 g per day. The estimated number of averted deaths ranged from 2.02 to 2.72 million for these analyses (Extended Data Table 1). Using an alternative method to estimate the proportion of discretionary salt resulted in a greater benefit from replacing discretionary salt and a smaller benefit from replacing non-discretionary salt but had little impact on the overall estimated benefit. Finally, assuming a higher prevalence of CKD stages 3–5 in low- and middle-income countries among individuals with diagnosed or treated hypertension led to slightly lower health gains, but the benefits remained substantial among these population groups (Extended Data Table 1).
Discussion
The global health impact of replacing regular salt with potassium-enriched salt projected by these analyses is large; more than 13 million deaths or new cases of CVD or CKD, and more than 69 million DALYs could be prevented each year if a global switch of regular salt to potassium-enriched salt could be implemented. The projected benefits are substantially greater than those anticipated from sodium reduction strategies alone14, reflecting the combined effects of reduced sodium exposure and increased potassium intake. A previous study using the data from the Salt Substitute and Stroke Study showed that potassium increase contributed a substantial portion of the effect15. While replacement of salt from both discretionary and non-discretionary sources prevents the largest disease burden, population-wide interventions targeted at either alone would also deliver large health gains. Intervention strategies that switch just discretionary salt in people with diagnosed hypertension achieve only about one-fifth of the potential benefit but may be more immediately achievable because they target populations already under clinical care and should minimize hyperkalaemia risk.
CVD is a frequent complication of CKD and hypertension is highly prevalent among this population group16. Our analysis projected that more than seven CVD deaths could be prevented for every one death that might be caused in people with CKD. Importantly, more than one quarter (0.75/2.79 million) of CVD deaths that might be prevented by a global switch to potassium-enriched salt are projected to be averted in people with CKD. There is a strong rationale for expecting increased rates of hyperkalaemia in people with advanced CKD and the potential harm from hyperkalaemia from a public intervention raises an ethical concern, although the assumed harms have never been demonstrated in trials. The estimates we made for population-wide intervention assumed that there was no capacity to prevent people with advanced CKD from using potassium-enriched salt, and the magnitude of the projected harm is likely to have been substantially overestimated as a consequence. In practice, those with advanced CKD are more likely to be symptomatic and diagnosed and routinely advised to limit salt intake and avoid products high in potassium. Strategies to ameliorate risks of hyperkalaemia include better screening for CKD, standardized warning labels on potassium-enriched salt products, listing of potassium-enriched salt when used as an ingredient in foods, and reporting of potassium content in the nutrient information panels on packaged foods. If hyperkalaemia risks are considered particularly high for a population, then an implementation strategy that focuses on switching discretionary salt use in people with hypertension should minimize risk, because clinician screening should prevent at-risk people with CKD from being recommended potassium-enriched salt. We assumed that 20% of diagnosed or treated hypertensive adults would be advised not to use potassium-enriched salt because of possible stage 3–5 CKD or hyperkalaemia risk. Because the true prevalence of stage 3–5 CKD in these groups probably varies across settings and may be lower in many countries, the projected benefits of these targeted strategies may be underestimated.
The largest anticipated absolute benefits are in countries such as China, India and Indonesia, which have large populations and a high burden of CVD and CKD. Targeting discretionary salt has greater overall benefits than targeting non-discretionary salt because a greater proportion of salt consumed worldwide derives from discretionary sources at present17. The recently launched WHO guideline on using lower-sodium salt substitutes with added potassium focuses on switching potassium-enriched salt for regular table salt as part of efforts to reduce sodium intake18. The importance of targeting non-discretionary salt will grow because economic development is strongly correlated with diets based on processed and restaurant foods17. For regions such as Europe and the USA, over 70% of salt intake comes from these sources. The already greater impact of targeting non-discretionary sources of salt in higher-income countries identified in these analyses presages a worldwide shift towards a greater overall impact of interventions targeting non-discretionary sources of salt over the coming years. The benefits we project from replacing non-discretionary salt may be over-optimistic because technical constraints in food production, regulatory considerations and industry uptake may limit implementation. However, the UK Committee on Toxicity considered that replacing up to 25–30% with potassium chloride in most food categories is feasible and safe19.
Full implementation of a switch to potassium-enriched salt will probably take decades but can learn from the prior switch of the world’s salt supply from regular salt to iodized salt that took almost a century20. The key practical challenges to achieving the health gains modelled here will be raising awareness among clinicians and the general community, increasing availability and supply in retail outlets, and reducing the price to that of regular salt. Ensuring the food industry switches to using potassium-enriched salt while actively engaging with governments, professional societies and guideline bodies to drive change will also be important. The price of potassium-enriched salt varies considerably but on average is double the cost of regular salt21. This increased cost relates to both potassium chloride being more expensive than sodium chloride and to potassium-enriched salt being marketed as a niche health product. This may have a higher impact on uptake in low and middle-income countries, although sodium chloride is a low-cost product and even at twice the price, potassium-enriched salt is a low-cost commodity. Economies of scale in potassium chloride production are expected to reduce unit production costs, consistent with the economics of capital-intensive potash mining22. Reducing price will be key to achieving industry uptake and to supporting public health efforts such as mandated government interventions. Raising awareness can be achieved by updating clinical guidelines for the management of hypertension, as done recently in Europe23 and the USA24 alongside education campaigns targeting end users in the food industry and government, as well as consumers.
Our study is the first to project the effects of switching regular salt use for potassium-enriched salt in 193 separate jurisdictions and worldwide. A key strength of the analysis is the use of a consistent method to evaluate the potential health impacts of a range of different implementation scenarios. The modelling pathway was adapted from previous studies but upgraded to include additional detail about dietary intake levels. This enabled better understanding of how the benefits and potential risks might trade off against each other for each country and for specific population groups. The analyses also enable us to account for uncertainty across the model pathway and generate more robust estimates of uncertainty.
The currency of the analyses is limited by being based on data from a few years ago and may not fully reflect the present status of each country. There is also a paucity of data describing the proportion of salt intake from discretionary versus non-discretionary sources and the comparisons between the effects of strategies targeting each source of sodium are therefore somewhat uncertain. Future country-specific modelling studies would benefit from additional country-specific data to provide more precise estimates for each nation as well as identify the most feasible strategies for implementation. The headline number of 2.96 million deaths averted were projected based on multiple assumptions about the relationships between sodium, potassium and BP, which probably fail to capture the full complexity of the effects in different populations. For example, the dose–response curves for the effects of sodium and potassium on BP may change with background use of antihypertensive medications. The evidence for the dose–response relationship between potassium supplementation and BP is also relatively sparse compared with that for sodium, particularly among individuals without hypertension, and projected health benefits were lower when the modelled effects of potassium were reduced. The data available to estimate the effects of potassium supplementation on hyperkalaemia risk were limited, although we used assumptions that were more likely to over-estimate than under-estimate potential harms. The model makes an estimate for just one point in time and does not account for future changes in population demographics and exposures. Finally, all the modelled scenarios would take many years and much effort to implement and do not represent immediately achievable health gains.
These analyses complement the recently released WHO guideline recommendations on the use of low-sodium salt substitutes with added potassium. The findings identify countries where switching to potassium-enriched salt might be prioritized and provide a quantitative indication of the likely balance of risks and benefits for each. A translational research agenda that shows how implementation can be achieved in diverse settings is now required.
Methods
Ethics
This modelling study used only published aggregated data and was not reviewed by an ethics committee.
Research design
This study used a comparative risk assessment framework adapted from our prior modelling studies11,12. The model first estimated the impact of strategies for replacing regular salt with potassium-enriched salt on dietary sodium and potassium intake for each country. The impact of an increase in dietary potassium intake was assumed to be derived only from replacement of regular salt with potassium-enriched salt, incorporating the proportion of sodium intake from discretionary salt versus other sources of sodium that are non-discretionary for each country. For every intervention scenario, the composition of the potassium-enriched salt was fixed as 75% sodium chloride and 25% potassium chloride because this is the ratio for which there is best evidence of clinical benefits and acceptability8. Based on the effects on dietary sodium and potassium intake, the model projected the impact on SBP and the subsequent effect of SBP change on the risks of CVD and CKD. In addition, the model estimated the increase in serum potassium among people with CKD stages G3–5 (estimated glomerular filtration rate (eGFR) <60) and the potential number of cardiovascular deaths caused by hyperkalaemia in this group.
Participants
For each of the 193 countries and territories, the adult population (aged 25+ years) was divided into 5-year age intervals from 25–29 to 90–94 years, with an additional group of 95+ years. Younger age groups were not included owing to their much lower burden of CVD and CKD, limited data on sodium and potassium intake, and sparse data describing the effects of sodium and potassium on SBP and risks of CVD and CKD in this group. The analyses were done separately for women and men and then combined.
Intervention scenarios
We estimated the impact of a switch to potassium-enriched salt under five scenarios: (1) worldwide replacement of all salt (including both discretionary salt and non-discretionary salt; (2) worldwide replacement of just discretionary salt; (3) worldwide replacement of just non-discretionary salt; (4) worldwide replacement of discretionary salt just for people diagnosed with hypertension (whether treated or not); and (5) worldwide replacement of discretionary salt just for people treated for hypertension (Extended Data Table 2).
For every scenario, we modelled the potential benefits mediated through SBP lowering. For the first three scenarios, we also modelled the potential harms mediated through hyperkalaemia among people with CKD stages G3–5. For scenarios (4) and (5), we modelled only the potential benefits on the assumption that clinical decision-making would prevent use of potassium-enriched salt amongst people with CKD stages G3–5. For these model estimates, we assumed arbitrarily that 20% of people under each scenario would not be recommended to use potassium-enriched salt owing to concerns about hyperkalaemia. The prevalence of CKD stages G3–5 among US adults with hypertension was 8.9% in 2015 to 201825, so the assumed 20% untreated is deemed conservative.
Data sources and key model assumptions
Supplementary Table 1 lists key model inputs. For pre-intervention mean sodium intake, we used country-specific estimates from the 2021 GBD study. Country-specific estimates of dietary sources of sodium (discretionary versus non-discretionary) were derived from a linear regression based on gross domestic product17 updated by substituting the 2010 World Bank gross domestic product figures used in the original report with 2021 data from the World Bank or the International Monetary Fund if data from the World Bank was not available.
For BP inputs to the model, we used country-, age- and sex-specific estimates and standard deviations of SBP from the 2021 GBD study. Corresponding hypertension prevalence estimates and the proportions treated were extracted from the 2019 Non-Communicable Disease Risk Factor Collaboration26. To estimate the effect of sodium reduction on SBP, we used linear dose–response relationships from a meta-regression of trials27 that enabled us to calculate the change in SBP achieved for a given sodium reduction, in a given age group, separately for individuals with and without hypertension. Dose–response data from salt substitute trials were not used because there were insufficient studies, and different compositions of potassium-enriched salt were used, which made it difficult to quantify the dose–response. In line with the WHO recommendation for maximum daily intake of 2 g of sodium per day, no additional effect on SBP was modelled for reductions below this level. To estimate the effect of increased potassium intake on SBP, we used data from a meta-analysis of randomized controlled trials28. Dose–response effects for potassium intake on SBP varied by baseline sodium intake level with stronger relationships and greater maximum achievable SBP falls in those with higher baseline sodium consumption28 (Supplementary Text 1). The effects of sodium reduction and increased potassium intake on SBP derived from these two estimation processes were assumed to be additive.
We used 2021 GBD Study country-, age- and sex-specific estimates for current CVD and CKD burden14. The associations of SBP changes with the risks of each type of CVD and CKD were based on the 2019 GBD Study29. The theoretical minimum risk exposure level for SBP was 110–115 mm Hg for each outcome, and no additional protective effect on CVD or CKD risk was modelled for SBP falling below this level.
For modelling potential harms of hyperkalaemia-related mortality, we used data on the prevalence of each stage of CKD (G3–5) for country-, age- and sex-specific population groups obtained from the 2021 GBD Study group, supplemented with data from a further study that enabled separate estimates to be made for stage G3a (eGFR 45 to 59) and stage G3b (eGFR 30 to 44) CKD30. The effects of increasing dietary potassium intake on serum potassium levels in people with stage G3a kidney disease were derived from a randomized trial31 and extrapolated to people with stages G3b, G4 and G5 using data from a cohort study32. A meta-analysis of cohort studies was used to translate the effects on serum potassium levels into risks of cardiovascular death33.
Statistical analysis
Following the methods used in our prior work11 (Supplementary Text 2), we estimated the potential number of averted deaths, new cases and DALYs attributable to CVD and CKD resulting from a shift in SBP distribution due to changes in dietary sodium and potassium intake. For scenarios 1–3, we then also estimated the additional deaths from CVD caused by increased intake of potassium in individuals with CKD stages G3–5, and the net averted deaths were calculated for each simulation as the difference between the deaths averted by SBP lowering and the deaths caused by hyperkalaemia. We also estimated prevented deaths from CVD in individuals with CKD stages G3–5 alone. We summed up CKD stage-specific effects to derive the total additional deaths for all people with CKD stage G3–5 attributable to hyperkalaemia in each country-, age- and sex-specific group. For new cases and DALYs, we excluded inflammatory heart diseases (rheumatic heart disease, endocarditis and other cardiomyopathy) from the estimations as the risks of these conditions are largely independent of BP.
Uncertainty analysis
We quantified uncertainty in all analyses with probabilistic sensitivity analyses using n = 1,000 Monte Carlo simulations, jointly incorporating uncertainties in input parameters (Supplementary Text 3). We derived the corresponding central estimate for each endpoint (including benefits, harms and net effects) from the 50th percentile and the 95% UI from the 2.5th and 97.5th centiles of 1,000 modelling runs. We also conducted 13 deterministic sensitivity analyses by varying key input data (Supplementary Table 2). All analyses were performed using R version 4.2.3 and RStudio version 2025.09.1 Build 401. Libraries ‘tidyverse’, ‘dplyr’, ‘stringr’, ‘splitstackshape’, ‘doParallel’, ‘data.table’, ‘doRNG’, ‘arrow’, ‘sf’, ‘rnaturalearth’ and ‘rnaturalearthdata’ were used.
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
All data used in this article are publicly available or can be requested from GBD. References to data sources are presented in Supplementary Table 1. Although most input data are publicly available on the GBD website, uploading them to another public repository may raise copyright concerns. Publicly available data can be shared upon request made to the corresponding author. For data requested from GBD, potential users can request from GBD or it can be shared with consent from GBD by making a request to the corresponding author.
Code availability
The code incorporates modules developed independently by two organizations under separate intellectual property arrangements and includes components that are reused across broader ongoing research programmes. As the authors do not hold exclusive rights to the codebase, public deposition cannot be undertaken without the agreement of all relevant intellectual property holders. Detailed descriptions of the model structure, assumptions, input data sources and analytical methods are provided in this article and its Supplementary Information. Researchers seeking to verify the findings reported in this study may request access to the code and related materials by contacting the corresponding author. Access is provided solely for the purpose of verifying the findings reported in this study. Researchers granted access must agree not to redistribute the code or use it for purposes other than verifying the findings reported in this study. Requests will be reviewed by the relevant organizations and a decision will normally be provided within 4 weeks of receipt.
References
Foreman, K. J. et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet 392, 2052–2090 (2018).
Vaduganathan, M., Mensah, G. A., Turco, J. V., Fuster, V. & Roth, G. A. The global burden of cardiovascular diseases and risk: a compass for future health. J. Am. Coll. Cardiol. 80, 2361–2371 (2022).
WHO Global Report on Sodium Intake Reduction (World Health Organization, 2023).
Qiao, J. et al. Global burden of non-communicable diseases attributable to dietary risks in 1990–2019. J. Hum. Nutr. Diet. 35, 202–213 (2022).
Reddin, C. et al. Global mean potassium intake: a systematic review and Bayesian meta-analysis. Eur. J. Nutr. 62, 2027–2037 (2023).
Guideline: Potassium Intake for Adults and Children (World Health Organization, 2012).
Kissock, K. R. et al. Knowledge, attitudes, and behaviours related to reduced-sodium salt: a systematic review. J. Hum. Hypertens. 40, 1–9 (2026).
Neal, B. et al. Effect of salt substitution on cardiovascular events and death. N. Engl. J. Med. 385, 1067–1077 (2021).
Yin, X. et al. Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis. Heart 108, 1608–1615 (2022).
Yuan, Y. et al. Salt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities: a cluster-randomized trial. Nat. Med. 29, 973–981 (2023).
Marklund, M. et al. Estimated population wide benefits and risks in China of lowering sodium through potassium enriched salt substitution: modelling study. Brit. Med. J. 369, m824 (2020).
Marklund, M. et al. Estimated benefits and risks of using a reduced-sodium, potassium-enriched salt substitute in India: a modeling study. Hypertension 79, 2188–2198 (2022).
Aminde, L. N. et al. Cost-effectiveness analysis of low-sodium potassium-rich salt substitutes in Indonesia: an equity modelling study. Lancet Reg. Health Southeast Asia 26, 100432 (2024).
GBD results. Institute for Health Metrics and Evaluation https://vizhub.healthdata.org/gbd-results/ (2021).
Huang, L. et al. The contribution of sodium reduction and potassium increase to the blood pressure lowering observed in the Salt Substitute and Stroke Study. J. Hum. Hypertens. 38, 298–306 (2024).
Burnier, M. & Damianaki, A. Hypertension as cardiovascular risk factor in chronic kidney disease. Circ. Res. 132, 1050–1063 (2023).
Bhat, S. et al. A systematic review of the sources of dietary salt around the world. Adv. Nutr. 11, 677–686 (2020).
Use of Lower-Sodium Salt Substitutes: WHO Guideline (World Health Organization, 2025).
Scientific Advisory Committee on Nutrition & Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment Potassium-Based Sodium Replacers: Assessment of the Health Benefits and Risks of Using Potassium-Based Sodium Replacers in Foods in the UK (Public Health England, 2017).
Kissock, K. R. et al. Switching the world’s salt supply-learning from iodization to achieve potassium enrichment. Adv. Nutr. 15, 100148 (2024).
Yin, X. et al. Availability, formulation, labeling, and price of low-sodium salt worldwide: environmental scan. JMIR Public Health Surveill. 7, e27423 (2021).
Fitzgerald, S. Unit economics of potash mining: a comprehensive overview. Investing Ideas https://investingideas.co/2024/10/25/unit-economics-of-potash-mining-a-comprehensive-overview/ (2024).
McEvoy, J. W. et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur. Heart J. 45, 3912–4018 (2024).
Gulati, M., Moore, M. M. & Cibotti-Sun, M. 2025 high blood pressure guideline-at-a-glance. J. Am. Coll. Cardiol. 86, 1560–1566 (2025).
Zeng, X., Zeng, Q., Zhou, L., Zhu, H. & Luo, J. Prevalence of chronic kidney disease among US adults with hypertension, 1999 to 2018. Hypertension 80, 2149–2158 (2023).
Zhou, B. et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 398, 957–980 (2021).
Mozaffarian, D. et al. Global sodium consumption and death from cardiovascular causes. New Engl. J. Med. 371, 624–634 (2014).
Filippini, T. et al. Potassium intake and blood pressure: a dose–response meta-analysis of randomized controlled trials. J. Am. Heart Assoc. 9, e015719 (2020).
Global Burden of Disease Collaborative Network Global Burden of Disease Study 2019 (GBD 2019) Relative Risks (Institute for Health Metrics and Evaluation, 2020).
Matsushita, K. et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 307, 1941–1951 (2012).
Turban, S. et al. Randomized trial on the effects of dietary potassium on blood pressure and serum potassium levels in adults with chronic kidney disease. Nutrients 13, 2678 (2021).
Ogata, S. et al. Association between dietary potassium intake estimated from multiple 24-hour urine collections and serum potassium in patients with CKD. Kidney Int. Rep. 8, 584–595 (2023).
Kovesdy, C. P. et al. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur. Heart J. 39, 1535–1542 (2018).
Acknowledgements
We acknowledge the GBD team for providing the input data for this work.
Funding
This work did not receive specific funding, but fellowship support received by individual authors enabled their contributions to the work. Specifically, L.H., A.E.S., L.N.A. and B.N. are supported by investigator grants from the National Health and Medical Research Council of Australia; E.J.H. is supported by the Dutch Kidney Foundation; K.T. is supported by the National Heart Foundation of Australia; M.M., K.M., T.M.B. and L.J.A. are supported by Resolve to Save Lives. Open access funding provided through UNSW Library.
Author information
Author notes
These authors contributed equally: Liping Huang, Xiaoyue Xu.
These authors jointly supervised this work: Bruce Neal, Matti Marklund.
Authors and Affiliations
The University of New South Wales, Sydney, New South Wales, Australia
Liping Huang, Xiaoyue Xu, Aletta E. Schutte, Jason H. Y. Wu, Kathy Trieu, Bruce Neal & Matti Marklund
The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
Liping Huang, Xiaoyue Xu, Aletta E. Schutte, Jason H. Y. Wu, Kathy Trieu, Bruce Neal & Matti Marklund
School of Population Health, University of New South Wales, Sydney, New South Wales, Australia
Xiaoyue Xu, Aletta E. Schutte & Jason H. Y. Wu
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Kunihiro Matsushita & Lawrence J. Appel
Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, USA
Kunihiro Matsushita, Tammy M. Brady, Lawrence J. Appel & Matti Marklund
Department of Paediatrics, Division of Nephrology, Johns Hopkins University School of Medicine and Dentistry, Baltimore, MD, USA
Tammy M. Brady & Matti Marklund
Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Lawrence J. Appel
Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, the Netherlands
Ewout J. Hoorn
School of Public Health, Harbin Medical University, Harbin, China
Maoyi Tian
Public Health and Economics Modelling Group, School of Medicine, Griffith University, Gold Coast, Queensland, Australia
Leopold N. Aminde
School of Public Health, Imperial College London, London, UK
Bruce Neal
Center for Human Nutrition, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Matti Marklund
Clinical Nutrition and Metabolism, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
Matti Marklund
Authors
- Liping Huang
- Xiaoyue Xu
- Kunihiro Matsushita
- Tammy M. Brady
- Lawrence J. Appel
- Ewout J. Hoorn
- Aletta E. Schutte
- Jason H. Y. Wu
- Maoyi Tian
- Leopold N. Aminde
- Kathy Trieu
- Bruce Neal
- Matti Marklund
Contributions
L.H., B.N. and M.M. conceptualized the study. L.H. conducted the formal analysis with supervision from M.M. X.X. led the work while L.H. took maternity leave for 6 months. B.N. and M.M. provided oversight of the work and helped draft the early iterations of the report. All other authors reviewed the paper and provided critical feedback.
Corresponding author
Correspondence to Liping Huang.
Ethics declarations
Competing interests
A.E.S. has received speaker honoraria from Servier, Abbott, Sanofi, AstraZeneca, Medtronic and Omron, and serves on scientific advisory boards for Medtronic, Alnylam, AstraZeneca, SiSU Health and Sky Labs. E.J.H. and T.M.B. have received author royalties from UpToDate. K.M., T.M.B., L.J.A. and M.M. received research support from Resolve to Save Lives. L.J.A. reports a consulting fee from GiveWell and honoraria from Wolters Kluwer, Cardiometabolic Health Congress Symposium, Cardiometabolic Health Congress Symposium and Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), outside the submitted work. K.M. received personal fees from Fukuda Denshi and RhythmX AI outside of the submitted work. M.M. reports funding from the World Health Organization and consulting fee from GiveWell, outside of the submitted work. The other authors delcare no competing interests.
Peer review
Peer review information
Nature Health thanks Tommaso Filippini and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available. Primary Handling Editor: Lorenzo Righetto, in collaboration with the Nature Health team.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
Extended Data Fig. 1 Types of deaths, new cases and disability-adjusted life years from cardiovascular disease or kidney disease prevented under different implementation scenarios for potassium-enriched salt, worldwide.
Stacked bars show the median annual numbers of net deaths, new cases, and DALYs averted across modelled diseases following replacement of regular salt (100% NaCl) with potassium-enriched salt (75% NaCl and 25% KCl) under different implementation scenarios. Estimates of net deaths averted were calculated as deaths prevented through blood pressure reduction minus deaths attributable to hyperkalaemia among individuals with stage G3–G5 CKD. Estimates of new cases and DALYs averted reflect only the health benefits mediated through blood pressure reduction. Values shown represent the median across 1,000 Monte Carlo simulations.
Extended Data Fig. 2 Numbers of new cases caused by cardiovascular disease or kidney disease prevented under different implementation scenarios for potassium-enriched salt for 193 countries and territories.
Maps illustrate the median annual number of new cases averted following replacement of regular salt (100% NaCl) with potassium-enriched salt (75% NaCl and 25% KCl) under different implementation scenarios. Median estimates were derived from 1,000 Monte Carlo simulations. Basemaps from Natural Earth (http://www.naturalearthdata.com).
Extended Data Fig. 3 Numbers of disability-adjusted life years caused by cardiovascular disease or kidney disease prevented under different implementation scenarios for potassium-enriched salt for 193 countries and territories.
Maps illustrate the median annual number of disability-adjusted life years averted following replacement of regular salt (100% NaCl) with potassium-enriched salt (75% NaCl and 25% KCl) under different implementation scenarios. Median estimates were derived from 1,000 Monte Carlo simulations. Basemaps from Natural Earth (http://www.naturalearthdata.com).
Extended Data Fig. 4 Proportion of national new cases from cardiovascular and kidney disease prevented under different implementation scenarios for potassium-enriched salt for 193 countries and territories.
Maps illustrate the estimated median proportion of national new cases from CVD and CKD averted following replacement of regular salt (100% NaCl) with potassium-enriched salt (75% NaCl and 25% KCl) under different implementation scenarios. The number of new cases under the status quo was estimated using data from the Global Burden of Disease Study 2021 and propagated through 1,000 Monte Carlo simulations. The proportion of new cases averted was calculated relative to the total number of new cases under the status quo from the modelled diseases and estimated in each simulation; the median across simulations is presented. Basemaps from Natural Earth (http://www.naturalearthdata.com).
Extended Data Fig. 5 Proportion of national disability-adjusted life years from cardiovascular disease and kidney disease prevented under different implementation scenarios for potassium-enriched salt for 193 countries and territories.
Maps illustrate the estimated median proportion of national disability-adjusted life years attributable to CVD and CKD averted following replacement of regular salt (100% NaCl) with potassium-enriched salt (75% NaCl and 25% KCl) under different implementation scenarios. The number of disability-adjusted life years under the status quo was estimated using data from the Global Burden of Disease Study 2021 and propagated through 1,000 Monte Carlo simulations. The proportion of disability-adjusted life years averted was calculated relative to the total number of disability-adjusted life years under the status quo from the modelled diseases and estimated in each simulation; the median across simulations is presented. Basemaps from Natural Earth (http://www.naturalearthdata.com).
Extended Data Fig. 6 Ten countries with the most averted deaths by replacing regular salt with potassium-enriched salt, by implementation scenarios.
The left-hand axis, the blue columns and the error bars show the number (and 95% uncertainty interval) for CVD and CKD deaths prevented by the intervention strategy in each country. The right-hand axis and the red lines show the cumulative proportion (solid lines) and 95% uncertainty intervals (dotted lines) for all deaths worldwide prevented by the intervention strategy as each country is included moving from left to right.
Extended Data Fig. 7 Ten countries with the most new cases averted by replacing regular salt with potassium-enriched salt, by implementation scenarios.
The left-hand axis, the blue columns and the error bars show the number (and 95% uncertainty interval) for CVD and CKD deaths prevented by the intervention strategy in each country. The right-hand axis and the red lines show the cumulative proportion (solid lines) and 95% uncertainty intervals (dotted lines) for all deaths worldwide prevented by the intervention strategy as each country is included moving from left to right.
Extended Data Fig. 8 Ten countries with the most averted disability-adjusted life years by replacing regular salt with potassium-enriched salt, by implementation scenarios.
The left-hand axis, the blue columns and the error bars show the number (and 95% uncertainty interval) for CVD and CKD deaths prevented by the intervention strategy in each country. The right-hand axis and the red lines show the cumulative proportion (solid lines) and 95% uncertainty intervals (dotted lines) for all deaths worldwide prevented by the intervention strategy as each country is included moving from left to right.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Huang, L., Xu, X., Matsushita, K. et al. Global health outcomes from replacing dietary sodium chloride with potassium-enriched salt. Nat. Health (2026). https://doi.org/10.1038/s44360-026-00216-9
Received: 08 June 2026
Accepted: 06 October 2026
Published: 04 November 2026
Version of record: 04 November 2026
DOI: https://doi.org/10.1038/s44360-026-00216-9
来源:Nature 健康护理主题 · nature.com